Symptoms of fatigue and sleepiness in major depressive disorder
Symptoms of fatigue and sleepiness in major depressive disorder
Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD). Individuals who complain of fatigue but do not have diagnosable depression are at a higher risk for developing MDD later in life than individuals who do not complain of fatigue. Fatigue and sleepiness also appear to be particularly difficult to treat, as they are often encountered as residual symptoms among MDD patients who have remitted following treatment with standard antidepressants. There are 3 main approaches for addressing fatigue and sleepiness in depression: first, prescribing antidepressant medications that are less likely to exacerbate these particular symptoms; second, prescribing antidepressant medications that are more likely to resolve these symptoms; third, the use of adjunctive treatments to specifically target residual fatigue and sleepiness in depression.
bupropion sustained-release, risk, physicians, modafinil augmentation, fluoxetine, depression, major depressive disorder, psychiatric comorbidity, primary-care, placebo-controlled trial, antidepressant, double-blind, antidepressants, European-society ii, adjunctive treatment, prescribing, selective serotonin
9-15
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Papakostas, G.I.
5660d4c8-bfda-46e3-a22a-9240da92cfbb
2006
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Papakostas, G.I.
5660d4c8-bfda-46e3-a22a-9240da92cfbb
Baldwin, D.S. and Papakostas, G.I.
(2006)
Symptoms of fatigue and sleepiness in major depressive disorder.
The Journal of Clinical Psychiatry, 67 (Supplement 6), .
Abstract
Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD). Individuals who complain of fatigue but do not have diagnosable depression are at a higher risk for developing MDD later in life than individuals who do not complain of fatigue. Fatigue and sleepiness also appear to be particularly difficult to treat, as they are often encountered as residual symptoms among MDD patients who have remitted following treatment with standard antidepressants. There are 3 main approaches for addressing fatigue and sleepiness in depression: first, prescribing antidepressant medications that are less likely to exacerbate these particular symptoms; second, prescribing antidepressant medications that are more likely to resolve these symptoms; third, the use of adjunctive treatments to specifically target residual fatigue and sleepiness in depression.
This record has no associated files available for download.
More information
Published date: 2006
Keywords:
bupropion sustained-release, risk, physicians, modafinil augmentation, fluoxetine, depression, major depressive disorder, psychiatric comorbidity, primary-care, placebo-controlled trial, antidepressant, double-blind, antidepressants, European-society ii, adjunctive treatment, prescribing, selective serotonin
Identifiers
Local EPrints ID: 62264
URI: http://eprints.soton.ac.uk/id/eprint/62264
PURE UUID: 28815763-f753-4e99-a84f-79c8a4e57bac
Catalogue record
Date deposited: 05 Sep 2008
Last modified: 28 Apr 2022 01:39
Export record
Contributors
Author:
G.I. Papakostas
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
